Rhumbline Advisers Makes New Investment in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Rhumbline Advisers bought a new stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,722 shares of the company’s stock, valued at approximately $118,000.

Separately, Bank of New York Mellon Corp acquired a new position in Contineum Therapeutics in the second quarter valued at approximately $356,000.

Contineum Therapeutics Stock Performance

Shares of NASDAQ:CTNM opened at $19.14 on Tuesday. The company has a 50 day moving average price of $18.68. Contineum Therapeutics, Inc. has a fifty-two week low of $13.27 and a fifty-two week high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last issued its earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.02). On average, analysts forecast that Contineum Therapeutics, Inc. will post -2.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada upped their target price on shares of Contineum Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Wednesday, August 14th.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).